Terms: = Ovarian cancer AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315 AND Treatment
11780 results:
1. Effects of Resveratrol on In Vivo ovarian cancer Cells Implanted on the Chorioallantoic Membrane (CAM) of a Chicken Embryo Model.
Chitcholtan K; Singh M; Tino A; Garrill A; Sykes P
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673959
[TBL] [Abstract] [Full Text] [Related]
2. High-Grade Serous ovarian cancer during Pregnancy: From Diagnosis to treatment.
Vivod G; Merlo S; Kovacevic N
Curr Oncol; 2024 Apr; 31(4):1920-1935. PubMed ID: 38668047
[TBL] [Abstract] [Full Text] [Related]
3. Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.
Sakhri S; Slimane M; Bouaziz H; Khessairi N; Boujelbene N; Ben Dhiab T
J Med Case Rep; 2024 Apr; 18(1):217. PubMed ID: 38654310
[TBL] [Abstract] [Full Text] [Related]
4. Granulosa cell tumor of the ovary: a series of 6 cases.
da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
[TBL] [Abstract] [Full Text] [Related]
5. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
6. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
7. Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.
Li N; Jin S; Wu J; Ji H; Du C; Liu B
PLoS One; 2024; 19(4):e0299504. PubMed ID: 38635517
[TBL] [Abstract] [Full Text] [Related]
8. Imaging for local recurrence of breast cancer.
Schlaiss T; Bott L; Herbert SL; Bartmann C; Kiesel M; Salmen J; Sauer ST; Christner SA; Petritsch B; Grunz JP; Woeckel A; Löb S; Diessner J
J Cancer Res Clin Oncol; 2024 Apr; 150(4):200. PubMed ID: 38627285
[TBL] [Abstract] [Full Text] [Related]
9. A New Model Including AMH Cut-off Levels to Predict Post-treatment ovarian Function in Early Breast cancer: A Prospective Cohort Study.
Omranipour R; Ahmadi-Harchegani F; Saberi A; Moini A; Shiri M; Jalaeefar A; Arian A; Seifollahi A; Madani M; Eslami B; Alipour S
Arch Iran Med; 2024 Feb; 27(2):96-104. PubMed ID: 38619033
[TBL] [Abstract] [Full Text] [Related]
10. Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D-Cys6-LHRH vedotin, against ovarian cancer cell lines.
Vankadara S; Ke Z; Wang S; Foo SY; Gunaratne J; Lee MA; Koh X; Chia CSB
Chem Biol Drug Des; 2024 Apr; 103(4):e14516. PubMed ID: 38618710
[TBL] [Abstract] [Full Text] [Related]
11. Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.
Elshami M; Jaber I; Alser M; Al-Slaibi I; Jabr H; Ubaiat S; Tuffaha A; Khader S; Khraishi R; Arafeh ZA; Al-Madhoun S; Alqattaa A; Yaseen A; El Hadi AA; Barhoush O; Hijazy M; Eleyan T; Alser A; Hziema AA; Shatat A; Almakhtoob F; Mohamad B; Farhat W; Abuamra Y; Mousa H; Adawi R; Musallam A; Albarqi SI; Abu-El-Noor N; Bottcher B
BMC Public Health; 2024 Apr; 24(1):1027. PubMed ID: 38609950
[TBL] [Abstract] [Full Text] [Related]
12. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
13. Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.
Chen Z; Wang C; Ding J; Yu T; Li N; Ye C
PLoS One; 2024; 19(4):e0291149. PubMed ID: 38603733
[TBL] [Abstract] [Full Text] [Related]
14. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
15. Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.
Kallio HM; Savolainen K; Virtanen T; Ryyppö L; Selin H; Martikainen P; Staff S; Kivinummi K; Sipola J; Vuorinen J; Nikkola J; Nykter M; Auranen A; Annala M
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38580393
[TBL] [Abstract] [Full Text] [Related]
16. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Martincuks A; Zhang C; Austria T; Li YJ; Huang R; Lugo Santiago N; Kohut A; Zhao Q; Borrero RM; Shen B; Cristea M; Wang EW; Song M; Rodriguez-Rodriguez L; Yu H
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580335
[TBL] [Abstract] [Full Text] [Related]
17. Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line.
Çoban HŞ; Çil N; Önder E; Abban Mete G
Mol Biol Rep; 2024 Apr; 51(1):485. PubMed ID: 38578399
[TBL] [Abstract] [Full Text] [Related]
18. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
Wu Z; Zhang Q; Jin Y; Zhang X; Chen Y; Yang C; Tang X; Jiang H; Wang X; Zhou X; Yu F; Wang B; Guan M
BMC Cancer; 2024 Apr; 24(1):411. PubMed ID: 38566028
[TBL] [Abstract] [Full Text] [Related]
19. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract] [Full Text] [Related]
20. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E; Huang TT; Nair JR; Zurcher G; McCoy A; Nousome D; Radke MR; Swisher EM; Lipkowitz S; Ibanez K; Donohue D; Malys T; Lee MJ; Redd B; Levy E; Rastogi S; Sato N; Trepel JB; Lee JM
Nat Commun; 2024 Mar; 15(1):2805. PubMed ID: 38555285
[TBL] [Abstract] [Full Text] [Related]
[Next]
